Ocular Therapeutix’s (OCUL) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Ocular Therapeutix (NASDAQ:OCUL) in a report published on Thursday, Benzinga reports. They currently have a $14.00 price objective on the biopharmaceutical company’s stock.

A number of other equities research analysts have also issued reports on OCUL. JMP Securities cut their price target on Ocular Therapeutix from $24.00 to $22.00 and set a market outperform rating for the company in a research note on Wednesday, May 8th. Piper Sandler reissued an overweight rating and issued a $15.00 price target on shares of Ocular Therapeutix in a report on Friday, June 21st. StockNews.com lowered shares of Ocular Therapeutix from a hold rating to a sell rating in a report on Friday, April 5th. Finally, TD Cowen cut shares of Ocular Therapeutix from a strong-buy rating to a hold rating in a research report on Friday, June 21st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Ocular Therapeutix currently has a consensus rating of Moderate Buy and an average price target of $15.83.

Ocular Therapeutix Stock Performance

Shares of OCUL stock traded down $0.27 during trading hours on Thursday, reaching $7.80. 814,226 shares of the company traded hands, compared to its average volume of 2,224,080. The firm has a 50-day moving average price of $6.65 and a 200 day moving average price of $6.92. The company has a market cap of $1.21 billion, a P/E ratio of -5.98 and a beta of 1.30. The company has a debt-to-equity ratio of 0.16, a current ratio of 21.39 and a quick ratio of 21.29. Ocular Therapeutix has a 12-month low of $2.00 and a 12-month high of $11.31.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The firm had revenue of $14.77 million for the quarter, compared to analysts’ expectations of $15.43 million. Ocular Therapeutix had a negative net margin of 192.61% and a negative return on equity of 76.64%. As a group, sell-side analysts predict that Ocular Therapeutix will post -0.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ocular Therapeutix

A number of hedge funds have recently bought and sold shares of OCUL. Trust Co. of Vermont increased its holdings in shares of Ocular Therapeutix by 20.0% in the 4th quarter. Trust Co. of Vermont now owns 6,000 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,000 shares during the last quarter. Atlas Capital Advisors LLC purchased a new stake in Ocular Therapeutix during the second quarter valued at approximately $34,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Ocular Therapeutix by 350.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,192 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 7,152 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Ocular Therapeutix by 142.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,756 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 5,730 shares during the period. Finally, Victory Capital Management Inc. bought a new position in shares of Ocular Therapeutix during the 4th quarter valued at approximately $45,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.